X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
beer (29) 29
biochemistry (29) 29
chemistry (29) 29
compositions or test papers therefor (29) 29
condition-responsive control in microbiological orenzymological processes (29) 29
enzymology (29) 29
measuring or testing processes involving enzymes, nucleicacids or microorganisms (29) 29
metallurgy (29) 29
microbiology (29) 29
mutation or genetic engineering (29) 29
physics (29) 29
processes of preparing such compositions (29) 29
spirits (29) 29
vinegar (29) 29
wine (29) 29
investigating or analysing materials by determining theirchemical or physical properties (28) 28
measuring (28) 28
testing (28) 28
index medicus (16) 16
organic chemistry (16) 16
peptides (16) 16
humans (15) 15
female (12) 12
adult (11) 11
oncology (11) 11
male (10) 10
middle aged (10) 10
aged (7) 7
information and communication technology [ict] specially adaptedfor specific application fields (7) 7
pharmacokinetics (6) 6
pharmacology & pharmacy (6) 6
aged, 80 and over (4) 4
phenylurea compounds - administration & dosage (4) 4
quinolines - administration & dosage (4) 4
treatment outcome (4) 4
administration, oral (3) 3
adolescent (3) 3
av-951 (3) 3
calculating (3) 3
cancer (3) 3
cci-779 (3) 3
cells (3) 3
computing (3) 3
counting (3) 3
drug therapy (3) 3
protein kinase inhibitors - administration & dosage (3) 3
renal-cell carcinoma (3) 3
research (3) 3
safety (3) 3
sirolimus - analogs & derivatives (3) 3
solid tumors (3) 3
vegf (3) 3
abridged index medicus (2) 2
angiogenesis inhibitors - administration & dosage (2) 2
angiogenesis inhibitors - adverse effects (2) 2
angiogenesis inhibitors - pharmacokinetics (2) 2
animals (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
breast neoplasms - drug therapy (2) 2
breast-cancer (2) 2
clinical trials (2) 2
confidence intervals (2) 2
disease-free survival (2) 2
double-blind (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
efficacy (2) 2
electric digital data processing (2) 2
gene expression profiling (2) 2
genetic aspects (2) 2
genetics (2) 2
healthy volunteers (2) 2
inhibitor (2) 2
injections, subcutaneous (2) 2
markov chains (2) 2
medical and health sciences (2) 2
medicin och hälsovetenskap (2) 2
medicine (2) 2
medicine, general & internal (2) 2
mice (2) 2
mtor (2) 2
oligonucleotide array sequence analysis (2) 2
pharmaceuticals (2) 2
phenylurea compounds - adverse effects (2) 2
phenylurea compounds - pharmacokinetics (2) 2
prognosis (2) 2
prospective studies (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein kinase inhibitors - pharmacokinetics (2) 2
protein kinase inhibitors - therapeutic use (2) 2
quality of life (2) 2
quinolines - adverse effects (2) 2
quinolines - pharmacokinetics (2) 2
receptors, vascular endothelial growth factor - antagonists & inhibitors (2) 2
rna, messenger - genetics (2) 2
rna, small interfering - adverse effects (2) 2
rna-mediated interference (2) 2
rnai therapeutics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 814 - 815
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 1, pp. 11 - 21
Hereditary transthyretin amyloidosis is caused by the deposition of misfolded transthyretin proteins in peripheral nerves and other tissues. This phase 3 trial... 
MEDICINE, GENERAL & INTERNAL | POLYNEUROPATHY | EFFICACY | TAFAMIDIS | SAFETY | LATE-ONSET | NATURAL-HISTORY | PROGRESSION | Prealbumin - genetics | Humans | Middle Aged | Male | Amyloid Neuropathies, Familial - therapy | Infusions, Intravenous - adverse effects | Aged, 80 and over | Adult | Female | Prealbumin - analysis | Severity of Illness Index | Double-Blind Method | Amyloid Neuropathies, Familial - complications | RNA, Small Interfering - adverse effects | Polyneuropathies - therapy | Disease Progression | Administration, Intravenous | Polyneuropathies - etiology | RNA, Small Interfering - therapeutic use | Least-Squares Analysis | Quality of Life | Aged | RNAi Therapeutics | Amyloid Neuropathies, Familial - blood | Edema - chemically induced | Walk Test | Gait Disorders, Neurologic - etiology | Care and treatment | Amyloidosis | Genetic aspects | Intravenous administration | Gait | Cardiomyopathy | RNA-mediated interference | Liver | Diabetes mellitus | Body weight | Transthyretin | Diabetic neuropathy | Neuropathy | Gene expression | Polyneuropathy | Quality of life | Medicine | Neurology | Hospitals | Nutritional status | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Assaigs clínics | Clinical trials | RNA | Amiloïdosi | Clinical Medicine | Neurologi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 07/2014, Volume 3, Issue 4, pp. 284 - 289
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 03/2014, Volume 3, Issue 2, pp. 158 - 162
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 07/2014, Volume 3, Issue 4, pp. 284 - 289
Journal Article
Journal Article
Clinical Colorectal Cancer, ISSN 1533-0028, 2015, Volume 14, Issue 1, pp. 18 - 24.e1
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 03/2015, Volume 4, Issue 2, pp. 137 - 142
The vascular endothelial growth factor (VEGF) pathway is associated with the promotion of endothelial cell proliferation, migration, and survival necessary for... 
pharmacokinetics | VEGF receptor | tyrosine kinase inhibitor | cytochrome P450 | drug interaction | Drug interaction | Pharmacokinetics | Tyrosine kinase inhibitor | Cytochrome P450 | AV-951 | SOLID TUMORS | VEGF | SORAFENIB | CANCER | RENAL-CELL CARCINOMA | KRN-951 | PHARMACOLOGY & PHARMACY | Quinolines - blood | Area Under Curve | Ketoconazole - administration & dosage | United States | Humans | Middle Aged | Half-Life | Male | Metabolic Clearance Rate | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Angiogenesis Inhibitors - blood | Cytochrome P-450 CYP3A Inducers - adverse effects | Quinolines - pharmacokinetics | Young Adult | Angiogenesis Inhibitors - administration & dosage | Rifampin - adverse effects | Receptors, Vascular Endothelial Growth Factor - metabolism | Phenylurea Compounds - adverse effects | Biotransformation | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | Phenylurea Compounds - pharmacokinetics | Rifampin - administration & dosage | Angiogenesis Inhibitors - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Administration, Oral | Angiogenesis Inhibitors - pharmacokinetics | Phenylurea Compounds - blood | Cytochrome P-450 CYP3A Inducers - administration & dosage | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Cytochrome P-450 CYP3A - metabolism | Models, Biological | Adolescent | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Ketoconazole - adverse effects | Quinolines - adverse effects | Vascular endothelial growth factor | Rodents | Index Medicus
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 03/2014, Volume 3, Issue 2, pp. 158 - 162
Tivozanib hydrochloride (tivozanib) is a potent, selective tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1, 2, and 3, with a... 
pharmacokinetics | renal cell cancer | tivozanib hydrochloride | food | solid tumors | Renal cell cancer | Tivozanib hydrochloride | Solid tumors | Pharmacokinetics | Food | AV-951 | TYROSINE KINASE INHIBITOR | PHARMACOLOGY & PHARMACY | Confidence intervals
Journal Article
Clinical Pharmacology in Drug Development, ISSN 2160-763X, 07/2012, Volume 1, Issue 3, pp. 102 - 109
Objective: To evaluate the absorption, metabolism, and excretion of tivozanib, a new investigational drug for renal cell carcinoma and solid malignancies.... 
pharmacokinetics | tivozanib | metabolism | excretion | absorption | TRIAL | SAFETY | VEGF | PHARMACOLOGY & PHARMACY
Journal Article
Maturitas, ISSN 0378-5122, 2007, Volume 58, Issue 4, pp. 366 - 376
Abstract Background Vaginal atrophy (VA) is a prevalent disorder in postmenopausal women that is characterized by decreased epithelial thickness, reduced... 
Internal Medicine | Obstetrics and Gynecology | Vagina | Expression profiling | Estradiol | Menopause | CELLS | vagina | MANAGEMENT | expression profiling | TISSUE | SYMPTOMS | GERIATRICS & GERONTOLOGY | OBSTETRICS & GYNECOLOGY | TRACT | HORMONE | menopause | DIFFERENTIATING EPITHELIA | PROTEINS | EXPRESSION | estradiol | REVEALS
Journal Article
Lecture Notes-Monograph Series, ISSN 0749-2170, 1/2003, Volume 40, pp. 343 - 366
In linkage disequilibrium (LD) mapping, use of information on multiple markers simultaneously is expected to lead to greater power to detect association and... 
Haplotypes | Datasets | Linkage disequilibrium | Medical genetics | Markov chains | Genetic loci | Population structure | Genetic Linkage and Linkage Disequilibrium | Markov models | Genotypes | Human genetics
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3822 - 3829
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 1, pp. 41 - 51
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.